IP Library › Granted Patent US 12,338,458
Granted Patent B2
US 12,338,458 · App. 16/616,099 · Granted Jun 24, 2025

Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy

Inventors: Richard John O'Reilly (Roxbury, CT); Bo Dupont (Harrison, NY); Aisha Nasreen Hasan (Blue Bell, PA); Annamalai Selvakumar (West Orange, NJ); Xiao-Rong Liu (Astoria, NY)
Assignee: Memorial Sloan Kettering Cancer Center
C12N5/0636A61K40/10A61K40/11A61K40/24A61K40/46C07K14/7051C12N5/0638C12N2501/2315C12N2502/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,338,458
App. No.
16/616,099
Granted
Jun 24, 2025
Kind
B2
Abstract

Provided herein are methods of generating antigen-specific T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, utilizing soluble IL-15/IL-15Rα complexes ex vivo, in cell culture during ex vivo sensitizing of T cells to the antigen or during ex vivo culturing of antigen-specific T cells. Also disclosed are antigen-specific T cells generated by such methods, and methods of treating a human patient using such antigen-specific T cells. Cell culture systems comprising human T cells, antigen-presenting cells, and soluble IL-15/IL-15Rα complexes are also provided.

Claims (29)

1. A method of generating an expanded population of cells comprising antigen-specific CD62L+central memory T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, comprising ex vivo culturing a population of human blood cells comprising human antigen-specific T cells over a period of time in culture in the presence of soluble IL-15/IL-15Rα complexes while in the absence of cells recombinantly expressing soluble IL-15/IL-15Rα complexes,

wherein the human antigen-specific T cells are specific to one or more antigens of the pathogen or cancer, and wherein the IL-15Rα subunit in the soluble IL-15/IL-15Rα complexes in the culture present with the population of human blood cells is a fragment of wild-type human IL-15Rα that retains the ability to bind to IL-15 but lacks the ability to be anchored to the cell membrane by itself, and

wherein the IL-15 subunit and the IL-15Rα subunit are in a 1:1 molar ratio.

2. The method of claim 1 , which further comprises adding the soluble IL-15/IL-15Rα complexes to the culture.

3. The method of claim 2 , wherein said adding soluble IL-15/IL-15Rα complexes is such that the concentration of IL-15 in culture supernatant is 10 2 to 10 3 pg/ml upon said adding.

4. The method of claim 2 , wherein said adding soluble IL-15/IL-15Rα complexes to the culture is done at the initiation of said ex vivo culturing and every 7 to 10 days thereafter during said ex vivo culturing.

5. The method of claim 1 , wherein the period of time in culture is at least 21 days.

6. The method of claim 5 , wherein the period of time in culture is 21 to 28 days.

7. The method of claim 1 , wherein the human antigen-specific T cells recombinantly express one or more chimeric antigen receptors (CARs) recognizing the one or more antigens.

8. The method of claim 1 , wherein the human antigen-specific T cells recombinantly express one or more T cell receptors (TCRs) recognizing the one or more antigens.

9. The method of claim 3 , wherein said adding the soluble IL-15/IL-15Rα complexes to the culture is done at the initiation of said ex vivo culturing and every 7 to 10 days thereafter during said ex vivo culturing.

10. The method of claim 3 , wherein the period of time in culture is at least 21 days.

11. The method of claim 4 , wherein the period of time in culture is at least 21 days.

12. The method of claim 9 , wherein the period of time in culture is at least 21 days.

13. The method of claim 10 , wherein the period of time in culture is 21 to 28 days.

14. The method of claim 11 , wherein the period of time in culture is 21 to 28 days.

15. The method of claim 12 , wherein the period of time in culture is 21 to 28 days.

16. The method of claim 1 , wherein the population of human blood cells at initiation of culture contains at least 90% central memory T cells (TCM cells).

17. The method of claim 1 , wherein the one or more antigens are one or more antigens of a pathogen.

18. The method of claim 17 , wherein the pathogen is a virus.

19. The method of claim 18 , wherein the virus is cytomegalovirus (CMV).

20. The method of claim 18 , wherein the virus is Epstein-Barr virus (EBV).

21. The method of claim 1 , wherein the one or more antigens are one or more antigens of a cancer.

22. The method of claim 21 , wherein the cancer is a blood cancer.

23. The method of claim 21 , wherein the cancer is a cancer of the breast, lung, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate, thyroid, brain, or skin.

24. The method of claim 21 , wherein the one or more antigens is Wilms Tumor 1 (WT1).

25. The method of claim 24 , wherein the cancer is multiple myeloma or plasma cell leukemia.

26. The method of claim 2 , which further comprises thawing the soluble IL-15/IL-15Rα complexes from a cryopreserved stock before adding the soluble IL-1 5/IL-15Rα complexes to the culture.

27. The method of claim 1 , wherein the human antigen-specific T cells are antigen-specific T cells generated by ex vivo sensitization.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2020
From: O'REILLY, RICHARD JOHN; DUPONT, BO; HASAN, AISHA NASREEN; SELVAKUMAR, ANNAMALAI; LIU, XIAO-RONG
To: MEMORIAL SLOAN KETTERING CANCER CENTER
Reel/Frame 052511/0085 →
Continuity (1)
Related Publication 20200157502A1 · May 21, 2020
References Cited (200)
US 6723695B1 · Burrows et al. · 2004 [cited by applicant]
US 8124084B2 · Lefrancois et al. · 2012 [cited by applicant]
US 8425898B2 · Sampson et al. · 2013 [cited by applicant]
US 8871191B2 · Pavlakis et al. · 2014 [cited by applicant]
US 8940288B2 · Lefrancois et al. · 2015 [cited by applicant]
US 9011835B2 · Sampson et al. · 2015 [cited by applicant]
US 9279017B2 · Raum · 2016 [cited by examiner]
US 10905743B2 · Qu · 2021 [cited by examiner]
US 20040265325A1 · Diamond et al. · 2004 [cited by applicant]
US 20140086888A1 · Heslop et al. · 2014 [cited by applicant]
US 20150093357A1 · Lefrancois et al. · 2015 [cited by applicant]
US 20150139945A1 · Lefrancois et al. · 2015 [cited by applicant]
US 20150359853A1 · Felber · 2015 [cited by examiner]
US 20190070264A1 · Qu · 2019 [cited by examiner]
CA 2970385C · 2023 [cited by applicant]
WO WO2007084342A2 · 2007 [cited by applicant]
WO WO2009002562A2 · 2008 [cited by applicant]
WO WO2010059253A2 · 2010 [cited by applicant]
WO WO2014066527A2 · 2014 [cited by applicant]
WO WO2016018920A1 · 2016 [cited by applicant]
WO WO20160955642 · 2016 [cited by examiner]
Chmielewski et al., Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells Review Article; Front. Immunol., published: Nov. 11, 2013; pp. 1-7. [cited by examiner]
Koehne et al., Abstracts / Biol Blood Marrow Transplant 22 (2016) S19eS481; S141 Targeting Wilms' Tumor 1 Protein Following CD34-Selected Allografts by Adoptive Transfer of Donor-Derived CTLs in Patients with Advanced M… [cited by examiner]
Stoklasek et al., Combined IL-15/IL-15Rα Immunotherapy Maximizes IL-15 Activity In Vivo J Immunol. Nov. 1, 2006; 177(9):6072-6080. [cited by examiner]
Motier et al Soluble Interleukin-15 Receptor (IL-15R)-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15R/. Hyperagonist IL-15IL-15R Fusion Proteins the Journal of Biological Chemistry vol. 281, No. 3… [cited by examiner]
“Biological therapy in treating patients at high-risk or with lymphoma, lymphoproliferative disease, or malignancies,” ClinicalTrials.gov, accessed at clinicaltrials.gov/ct2/show/NCT00002663?term=NCT00002663&rank=1, fir… [cited by applicant]
“Busulfan, melphalan, fludarabine and T-cell depleted allogeneic hematopoietic stem cell transplantation followed by post transplantation donor lymphocyte infusions,” ClinicalTrials.gov, accessed at clinicaltrials.gov/c… [cited by applicant]
“Dose escalation trial of WT1-sensitized T cells for residual or relapsed leukemia after allogeneic hematopoietic progenitor cell transplantation,” ClinicalTrials.gov, accessed at clinicaltrials.gov/ct2/show/NCT00620633… [cited by applicant]
“Dose escalation trial of WT1-specific donor-derived T cells following—cell depleted allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory multiple myeloma,” ClinicalTrials.gov, access… [cited by applicant]
“Form S-1 Registration Statement,” filed with the United States Securities and Exchange Commission by Atara Biotherapeutics, Inc., dated Jun. 29, 2015, 203 pages. [cited by applicant]
“Primary transplant donor derived CMVpp65 specific T-cells for the treatment of CMV infection or persistent CMV viremia after allogeneic hematopoietic stem cell transplantation,” ClinicalTrials.gov, accessed at clinical… [cited by applicant]
“Therapeutic effects of Epstein-Barr virus immune T-lymphocytes derived from a normal HLA-compatible or partially-matched third-party donor in the treatment of EBV lymphoproliferative disorders and EBV-associated malign… [cited by applicant]
“Trial of third party donor derived CMVpp65 specific T-cells for the treatment of CMV infection or persistent CMV viremia after allogeneic hematopoietic stem cell transplantation,” ClinicalTrials.gov, accessed at clinic… [cited by applicant]
Agger et al., Jan. 2007, “T cell homing to tumors detected by 3D-coordinated positron emission tomography and magnetic resonance imaging,” J Immunother. 30(1):29-39. [cited by applicant]
Ahmed and Gray, Apr. 1996, “Immunological memory and protective immunity: understanding their relation,” Science. 272(5258):54-60. [cited by applicant]
Amarnath and Fowler, Jan. 2012, “Harnessing autophagy for adoptive T cell therapy,” Immunotherapy, 4(1):1-4. [cited by applicant]
American Association for Cancer Research (AACR) Press Release entitled “New T cell-based immunotherapy shows promise for lethal stem cell transplant complication,” dated Apr. 19, 2015, 3 pages. [cited by applicant]
Balduzzi et al., Jul. 2011, “Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient,” Bone Marrow Transplantation, 46(7):987-992. [cited by applicant]
Bao et al., Apr. 2012, “Adoptive immunotherapy with CMV specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections,” Journal of Immunotherapy, 35(3):293-298. [cited by applicant]
Barker et al., Dec. 2010, “Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes,” Blood. 116(23):5045-5049. [cited by applicant]
Bergamaschi et al., Feb. 2008, “Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity,” J Biol Chem. 283(7):4189-4199. [cited by applicant]
Berger et al., Jan. 2008, “Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates,” J Clin Invest. 118(1):294-305. [cited by applicant]
Blyth et al., Nov. 2011, “BK virus-specific T cells for use in cellular therapy show specificity to multiple antigens and polyfunctional cytokine responses,” Transplantation, 92(10):1077-1084. [cited by applicant]
Bonnet and Dick, Jul. 1997, “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” Nat Med. 3(7):730-737. [cited by applicant]
Bontadini, A., Apr. 2012, “HLA techniques: typing and antibody detection in the laboratory of immunogenetics,” Methods. 56(4):471-476. [cited by applicant]
Brentjens et al., Sep. 2007, “Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts,” Clin Cancer Res. 13(18 Pt 1):5426-5435. [cited by applicant]
Budhu et al., Jan. 2010, “CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues,” J Exp Med. 207(1):223-235. [cited by applicant]
Burkett et al., Oct. 2004, “Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis,” J Exp Med. 200(7):825-834. [cited by applicant]
Burns and Crawford, Sep. 2004, “Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease,” Blood Reviews, 18(3):193-209. [cited by applicant]
Caruso et al., Jun. 2016, “Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor,” J Immunother. 39(5):205-217. [cited by applicant]
Chertova et al., Jun. 2013, “Characterization and favorable in vivo properties of heterodimeric soluble IL-15⋅IL-15Rα cytokine compared to IL-15 monomer,” J Biol Chem. 288(25):18093-18103. [cited by applicant]
Cobbold et al., Aug. 2005, “Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers,” The Journal of Experimental Medicine, 202(3):379-386. [cited by applicant]
Comoli et al., Apr. 2002, “Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of acti… [cited by applicant]
Cortivo et al., Nov. 2012, “Anti CMV and/or anti adenovirus IFN-g-positive CD4+ CD8+ T lymphocytes for treatment of viral infections after allogeneic HSC transplantation: first results,” Blood, 120(21):1906. [cited by applicant]
Doubrovina et al., Nov. 2004, “In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity,” C… [cited by applicant]
Doubrovina et al., Nov. 2007, “Leukemia-reactive cytotoxic CD8+ and CD4+ T-cells specific for novel WT-1 epitopes are generated in vitro by sensitization with overlapping pentadecapeptides (15-mers) spanning the wilms t… [cited by applicant]
Doubrovina et al., Aug. 2012, “Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias,” Blood. 120(8):1633-1646. [cited by applicant]
Doubrovina et al., Mar. 2012, “Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation,” Blood, 119(11):2644-2656 (Published on… [cited by applicant]
Dubois et al., Nov. 2002, “IL-15Ralpha recycles and presents IL-15 in trans to neighboring cells,” Immunity. 17(5):537-547. [cited by applicant]
Dunn, PP. Dec. 2011, “Human leucocyte antigen typing: techniques and technology, a critical appraisal,” Int J Immunogenet. 38(6):463-473. [cited by applicant]
Einsele et al., Jun. 2002, “Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy,” Blood, 99(11):3916-3922. [cited by applicant]
Eiz-Vesper et al., Jan. 2013, “Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry,” Frontiers in Immunology, 3:410. [cited by applicant]
Epardaud et al., Apr. 2008, “Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells,” Cancer Res. 68(8):2972-2983. [cited by applicant]
Epstein et al., 1994, “Human neural xenografts: progress in developing an in-vivo model to study human immunodeficiency virus (HIV) and human cytomegalovirus (HCMV) infection,” Adv Neuroimmunol. 4(3):257-260. [cited by applicant]
Feuchtinger et al., Nov. 2010, “Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantatio… [cited by applicant]
Gahn et al., Jan. 2002, “Immunotherapy to reconstitute immunity to DNA viruses,” Seminars in Hematology, 39(1):41-47. [cited by applicant]
Gandhi et al., May 2007, “Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders,” American Journal of Transplantation, 7(5):1293-1299 (Published online Apr. … [cited by applicant]
Gattinoni et al., Jun. 2005, “Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells,” J Clin Invest. 115(6):1616-1626. [cited by applicant]
Gerdemann et al., Aug. 2012, “Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections,” Mol Ther. 20(8):1622-1632. [cited by applicant]
Gerdemann et al., Jan. 2013, “Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation,” Blood, 121(1):207-218. [cited by applicant]
Gottschalk et al., Jan. 2015, “Adoptive T-cell immunotherapy,” Current Topics in Microbiology and Immunology, 391:427-454. [cited by applicant]
Gupta et al., “Treatment of cytomegalovirus (CMV) retinitis with third party donor-derived CMV-specific cytotoxic T-lymphocytes,” meeting abstract for ASRS 33rd Annual Meeting held Jul. 11- 14, 2015, Vienna, Austria, re… [cited by applicant]
Gupta et al., Jan. 2015, “Treatment of cytomegalovirus retinitis with cytomegalovirus-specific T-lymphocyte infusion,” Ophthalmic Surgery, Lasers & Imaging Retina, 46(1):80-82. [cited by applicant]
Haque et al., Oct. 2001, “Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells,” Transplantation, 72(8):1399-1402. [cited by applicant]
Haque et al., Aug. 2002, “Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells,” Lancet, 360(9331):436-442. [cited by applicant]
Haque et al., Aug. 2007, “Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial,” Blood. 110(4):1123-1131. [cited by applicant]
Hasan et al., Aug. 2009, “A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy,” The Journal … [cited by applicant]
Hasan et al., Feb. 2010, “IL-15 Enhances In-Vitro Expansion and Functional Activity of Antigen-Specific Effector Memory T Cells (TEM) While Coexpression of IL-15 and IL-15 R on Antigen Presenting Cells Also Promotes Enr… [cited by applicant]
Hasan et al., Nov. 2013, “Generation and characterization of a third party GMP grade bank of CMV specific T-cells for adoptive immunotherapy of CMV infections in recipients of HSCT from cord blood or seronegative donors… [cited by applicant]
Hasan et al., Dec. 2014, “Banked, GMP grade third party T-cell lines specific for CMVpp65 epitopes presented by certain prevalent HLA alleles more consistently clear CMV infections in a genetically heterogeneous populat… [cited by applicant]
Hasan et al., Feb. 2014, “Generation and characterization of a third party GMP grade bank of CMV specific T-cells for adoptive immunotherapy of CMV infections in recipients of HSCT from cord blood or seronegative donors… [cited by applicant]
Hasan et al., Nov. 2016, “Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8(+) T cells for adoptive immunotherapy of cancer and infections,” Clin … [cited by applicant]
Hasan, “Banked, GMP grade third party T-cell lines specific for CMVpp65 epitopes presented by certain prevalent HLA alleles more consistently clear CMV infections in a genetically heterogeneous population of HSCT recipi… [cited by applicant]
Heslop et al., May 1996, “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nat Med. 2(5):551-555. [cited by applicant]
Heslop et al., Feb. 2010, “Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients,” Blood, 115(5):925-935 (Published online Oct. 30, 2009). [cited by applicant]
Holmes-Liew et al., Mar. 2015, “Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation,” Clinical & Translational Immunology, 4(3):e35. [cited by applicant]
Huang et al., May-Jun. 2005; “Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression,” J Immunother. 28(3):258-267. [cited by applicant]
Humar et al., Dec. 2009, “Cytomegalovirus in solid organ transplant recipients,” American Journal of Transplantation, 9(Suppl 4):S78-S86. [cited by applicant]
Hunder et al, Jun. 2008, “Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1,” N Engl J Med. 358(25):2698-2703. [cited by applicant]
Hungtington et al., Jan. 2009, “IL-15 trans-presentation promotes human NK cell development and differentiation in vivo,” J Exp Med. 206(1):25-34. [cited by applicant]
Huntington et al., Apr. 2011, “IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo,” Proc Natl Acad Sci U S A. 108(15):6217-6222. [cited by applicant]
Imamura et al., Aug. 2014, “Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15,” Blood. 124(7):1081-1088. [cited by applicant]
Inoda et al., Apr. 2011, “Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells,” Am J Pathol. 178(4):1805-1813. [cited by applicant]
International Search Report dated Nov. 29, 2019 of International Patent Application No. PCT/US2017/034364, filed May 25, 2017 (published as WO2018/217203), 5 pages. [cited by applicant]
Kawakami et al., Oct. 2005, “A case of immune recovery vitritis induced by donor leukocyte infusion for the treatment of cytomegalovirus retinitis,” European Journal of Haematology, 75(4):352-354. [cited by applicant]
Kennedy et al., Mar. 2000, “Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice,” J Exp Med. 191(5):771-780. [cited by applicant]
Kerry et al., Nov. 2003, “Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement,” J Immunol. 171(9):4493-4503. [cited by applicant]
Khanna et al., Aug. 1999, “Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease,” Proceedings of the Nation… [cited by applicant]
Kim et al., Nov. 2007, “Dual roles of IL-15 in maintaining IL-7RalphalowCCR7-memory CD8+ T cells in humans via recovering the phosphatidylinositol 3-kinase/AKT pathway,” J Immunol. 179(10):6734-6740. [cited by applicant]
Kiss et al., “Treatment of cytomegalovirus (CMV) retinitis with systemic infusion of third party donor-derived CMV-specific cytotoxic T-lymphocytes,” meeting abstract for The Retina Society 48th Annual Scientific Meetin… [cited by applicant]
Klebanoff et al., Jul. 2005, “Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells,” Proc Natl Acad Sci U S A. 102(27):9571-9576. [cited by applicant]
Koehne et al., Jul. 2000, “Rapid selection of antigen-specific T lymphocytes by retroviral transduction,” Blood. 96(1):109-117. [cited by applicant]
Koehne et al., Mar. 2002, “Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic p… [cited by applicant]
Koehne et al., Apr. 2003, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat Biotechnol. 21(4):405-413. [cited by applicant]
Koehne et al., Sep. 2015, “Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia,” Biology of Blood and Marrow Transplantation, 2… [cited by applicant]
Kokaji et al., Apr. 2008, “IL-15 transpresentation augments CD8+ T cell activation and is required for optimal recall responses by central memory CD8+ T cells,” J Immunol. 180(7):4391-4401. [cited by applicant]
Kozak, M., Aug. 1987, “At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells,” J Mol Biol. 196(4):947-950. [cited by applicant]
Kunert et al., Nov. 2013, “TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu,” Front Immunol. 4:363. [cited by applicant]
Kuo et al., “WS/PP-109-04: Role of central memory and effector memory CD8 T cells in adoptive cell therapy,” presented at 14th International Congress of Immunology, Friday Aug. 27, 2010, Kobe, Japan, Poster Abstract, 3 … [cited by applicant]
Kuo et al. “WS/PP-109-04 Role of central memory and effector memory CD8 T cells in adoptive cell therapy,” presented at 14th International Congress of Immunology, Monday Aug. 23, 2010, Kobe, Japan, Poster Abstract, 3 pa… [cited by applicant]
Lange et al., Jan. 2014, “Cost-efficient high-throughput HLA typing by MiSeq amplicon sequencing,” BMC Genomics. 15: 63. [cited by applicant]
Lapidot et al., Feb. 1994, “A cell initiating human acute myeloid leukaemia after transplantation into SCID mice,” Nature. 367(6464):645-648. [cited by applicant]
Latouche and Sadelain, Apr. 2000, “Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells,” Nat Biotechnol. 18(4):405-409. [cited by applicant]
Leen et al, Jun. 2013, “Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation,” Blood, 121(26):5113-5123 (Published online Apr. 22,… [cited by applicant]
Leen et al., Oct. 2006, “Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals,” Nature Medicine, 12(10):1160-1166 (Published onl… [cited by applicant]
Lischka et al., Mar. 2010, “In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246,” Antimicrob Agents Chemother. 54(3):1290-1297. [cited by applicant]
Liu et al., May 2013, “IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner,” Proc Natl Acad Sci U S A. 110(20):8158-8163. [cited by applicant]
Louis et al., Nov.-Dec. 2010, “Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma,” Journal of Immunotherapy, 33(9):983-990. [cited by applicant]
Lucas et al., Mar. 1996, “The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation,” Blood, 87(6):2594-2603. [cited by applicant]
Macesic et al., Mar. 2015, “Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient,” American Journal of Transplantation, 15(3):827-832 (Published on… [cited by applicant]
Micklethwaite et al., Jun. 2007, “Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation,” Biology of Blood and Marr… [cited by applicant]
Mocarski et al., Jan. 1993, “Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication,” Proc Natl Acad Sci U S A. 90(1):104-108. [cited by applicant]
Morgan et al., Oct. 2006, “Cancer regression in patients after transfer of genetically engineered lymphocytes,” Science. 314(5796):126-129. [cited by applicant]
Mortier et al., May 2008, “IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation,” J Exp Med. 205(5):1213-1225. [cited by applicant]
Mortier et al., Nov. 2009, “Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets,” Immunity. 31(5):811-822. [cited by applicant]
Mortier et al., Jan. 2006, “Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma,” Hyperagonist IL-15×IL-15R alpha fusion proteins, J Bio… [cited by applicant]
Mortier et al., Aug. 2004, “Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist,” J Immunol. 173(3):1681-1688. [cited by applicant]
Oh et al., Mar. 2003, “Selective induction of high avidity CTL by altering the balance of signals from APC,” J. Immunol. 170(5):2523-2530. [cited by applicant]
O'Reilly et al., May 2007, “Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants,” Immunologic Research, 38(1-3):237-250. [cited by applicant]
O'Reilly et al., Jun. 2010, “Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation,” Seminars in Immunology, 22(3):162-172 (Publ… [cited by applicant]
O'Reilly et al., Sep. 2011, “Novel strategies for adoptive therapy following HLA disparate transplants,” Best Practice & Research Clinical Haematology, 24(3):381-391. [cited by applicant]
O'Reilly et al., Jun. 2015, “T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells,” Bone Marrow Transplant, 50(Suppl 2):S43-S50. [cited by applicant]
O'Reilly, meeting abstract for the oral presentation on Oct. 31, 2014 at the 76th Annual Meeting of the Japanese Society of Hematology, held Oct. 31-Nov. 2, 2014, Osaka, Japan, 1 page. [cited by applicant]
Papadopoulou et al., Jun. 2014, “Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT,” Science Translational Medicine, 6(242):242ra83. [cited by applicant]
Park et al., Nov. 2011, “Treating cancer with genetically engineered T cells,” Trends Biotechnol. 29(11):550-557. [cited by applicant]
Peggs et al., Oct. 2003, “Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines,” Lancet, 362(9393):1375-1377. [cited by applicant]
Perna et al., Jan. 2013, “Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma,” Clin Cancer Res. 19(1):106-117. [cited by applicant]
Petersen et al., May-Jun. 2006, “Accumulation in tumor tissue of adoptively transferred T cells: A comparison between intravenous and intraperitoneal injection,” J Immunother. 29(3):241-249. [cited by applicant]
Votavola et al., May-Jun. 2014, “Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera,” Immunol Lett. 159(1-2):1-10. [cited by applicant]
Prockop et al., “Banked EBV-specific T-cells from HLA-partially matched normal donors induce durable remissions of rituximab refractory EBV+ B-cell lymphomas post hematopoietic and organ allografts,” meeting abstract fo… [cited by applicant]
Prockop et al., “Epstein-Barr virus-specific cytotoxic T lymphocytes for treatment of rituximab-refractory Epstein-Barr virus-associated lymphoproliferative disorder,” meeting abstract for the 2015 AACR Anual Meeting he… [cited by applicant]
Prockop et al., Dec. 2014, “Third party donor derived CMV specific T cells for the treatment of refractory CMV viremia and disease after hematopoietic stem cell transplant,” Blood, 124(21):184. [cited by applicant]
Prockop et al., Feb. 2014, “Third party donor derived EBV specific T cells for the treatment of refractory EBV-related post-transplant lymphomas,” Biology of Blood and Marrow Transplantation, 20(2):S49-S50. [cited by applicant]
Prockop et al., 2014, “Third party donor derived CMV specific T cells for the treatment of refractory CMV viremia and disease after hematopoietic stem cell transplant,” meeting abstract for the 56th American Society of … [cited by applicant]
Prockop et al., Dec. 2015, “Successful treatment of refractory CMV chorioretinitis and meningoencephalitis with adoptive transfer of third party CMVpp65 specific T-cell lines,” Blood, 126(23):3157. [cited by applicant]
Prockop et al., 2015, “Successful treatment of refractory CMV chorioretinitis and meningoencephalitis with adoptive transfer of third party CMVpp65 specific T-cell lines,” meeting abstract for the 57th American Society … [cited by applicant]
Prockop, “3rd party CMV specific T cells for the treatment of refractory CMV viremia and disease after HSCT,” slide presentation on Dec. 7, 2014 at the 56th ASH Annual Meeting held Dec. 6-9, 2014, San Francisco, Califor… [cited by applicant]
Prockop, “Adoptive immunotherapy with banked virus specific 3rd party donor T-cells for CMV infections and EBV LPD complicating hematopoietic cell transplants,” slide presentation on Oct. 31, 2014 at the 76th Annual Mee… [cited by applicant]
Prockop, “Banked EBV-specific T-cells from HLA-partially matched normal donors induce durable remissions of rituximab refractory EBV+ B-cell lymphomas post hematopoietic and organ allografts,” slide presentation on Jun.… [cited by applicant]
Prockop, “Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (EBV-CTLs) for treatment of rituximab-refractory EBV-associated lymphoproliferative disorder (EBV-LPD),” slide presentation on Apr. 19, 2015 at the 201… [cited by applicant]
Prockop, “Third party donor derived EBV specific T cells for the treatment of refractory lymphoma in immunodeficient recipients,” slide presentation on Mar. 1, 2014 at the ASBMT 2014 BMT Tandem Meetings held Feb. 26-Mar… [cited by applicant]
Prockop, “Third party donor T cells for the treatment of CMV infection and EBV lymphoma in immunodeficient patients,” slide presentation on May 22, 2014 at the 9th Meeting of the EBMT Pediatric Diseases WP, held May 21-… [cited by applicant]
Qasim et al., May 2013, “Interferon-γ capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation,” British Journal of Haematology, 161(3):449-452 (Published online … [cited by applicant]
Quinn et al., Feb. 2015, “Memory T cells specific for murine cytomegalovirus re-emerge after multiple challenges and recapitulate immunity in various adoptive transfer scenarios,” J Immunol. 194(4):1726-1736. [cited by applicant]
Ramos et al., Jan. 2013, “Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies,” Journal of Immunotherapy, 36(1):66-76. [cited by applicant]
Rodriguez-Tarduchy et al., Sep. 1990, “Regulation of apoptosis in interleukin-3-dependent hemopoietic cells by interleukin-3 and calcium ionophores,” EMBO J. 9(9):2997-3002. [cited by applicant]
Romano et al., May 2012, “Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1,” Blood. 31;119(22):5182-5190. [cited by applicant]
Rooney et al., Jan. 1995, “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” Lancet, 345(8941):9-13. [cited by applicant]
Rooney et al., Sep. 1998, “Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients,” Blood, 92(5):1549-1555. [cited by applicant]
Rosenberg and Dudley, Oct. 2004, “Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes,” Proc Natl Acad Sci U S A. 101 Suppl 2:14639-14645. [cited by applicant]
Rosenberg et al., Dec. 1988, “Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report,” N Engl J Med. 319(25):1676-1680. [cited by applicant]
Rowley et al., Feb. 2009, “Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis,” Eur J Immunol. 39(2):491-506. [cited by applicant]
Roychowdhury et al., Nov. 2004, “Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2,” Cancer Res. 64(21):8062-8067. [cited by applicant]
Rubinstein et al., Jun. 2006, Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 103(24): 9166-9171. [cited by applicant]
Sadelain et al., Apr. 2013, “The basic principles of chimeric antigen receptor design,” Cancer Discov. 3(4):388-398. [cited by applicant]
Sato et al., Jun. 2007, “Genome sequencing and genome resources in model legumes,” Plant Physiol. 144(2):588-593. [cited by applicant]
Schluns and Lefrancois, Apr. 2003, “Cytokine control of memory T-cell development and survival,” Nat Rev Immunol. 3(4):269-279. [cited by applicant]
Schluns et al., May 2002, “Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells,” J Immunol. 168(10):4827-4831. [cited by applicant]
Schluns et al., Feb. 2004, “Transregulation of memory CD8 T-cell proliferation by IL-15Ralpha+ bone marrow-derived cells,” Blood. 103(3):988-994. [cited by applicant]
Schmitt et al., Mar. 2011, “Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell tr… [cited by applicant]
Sharpe and Mount, Apr. 2015, “Genetically modified T cells in cancer therapy: opportunities and challenges,” Dis Model Mech. 8(4):337-350. [cited by applicant]
Sili et al., Jan. 2012, “Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hemat… [cited by applicant]
Sprent and Surh, Apr. 2001, “Generation and maintenance of memory T cells,” Curr Opin Immunol. 13(2):248-254. [cited by applicant]
Stauss et al., Oct. 2015, “Cancer gene therapy with T cell receptors and chimeric antigen receptors,” Curr Opin Pharmacol. 24:113-118. [cited by applicant]
Stemberger et al., Jul. 2014, “Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy,” Blood. 124(4):628-637. [cited by applicant]
Stoklasek et al., Nov. 2006, “Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo,” J Immunol. 177(9):6072-6080. [cited by applicant]
Stone et al., 2012, “T cell receptor engineering,” Methods Enzymol. 503:189-222. [cited by applicant]
Straathof et al., Mar. 2005, “Treatment of nasopharyngeal carcinoma with Epstein-Barr virus—specific T lymphocytes,” Blood, 105(5):1898-1904 (Published online Nov. 12, 2004). [cited by applicant]
Sukdolak et al., Oct. 2013, “CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome,” Biology of Blood and Marrow Transplantation, 1… [cited by applicant]
Surh and Sprent, Dec. 2008, “Homeostasis of naive and memory T cells,” Immunity, 19;29(6):848-862. [cited by applicant]
Tamzalit et al., Jun. 2014, IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells. Proc Natl Acad Sci U S A 111(23):8565-8570. [cited by applicant]
Traitanon et al., Jun. 2014, “IL-15 induces alloreactive CD28(−) memory CD8 T cell proliferation and CTLA4-Ig resistant memory CD8 T cell activation,” Am J Transplant. 14(6):1277-1289. [cited by applicant]
Trivedi et al., Apr. 2005, “Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy,” Blood, 105(7):2793-2801 (Published online Oct.… [cited by applicant]
Tse and Kwong, Jan. 2015, “Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target,” Experimental & Molecular Medicine, 47:e136. [cited by applicant]
Uhlin et al., Oct. 2012, “Rapid salvage treatment with virus-specific T cells for therapy-resistant disease,” Clinical Infectious Diseases, 55(8):1064-1073 (Published online Jul. 17, 2012). [cited by applicant]
Van Den Bergh et al., Feb. 2017, “IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: The upswing of IL-15 transpresentation,” Pharmacol Ther. 170:73-79. [cited by applicant]
Waldmann et al., Feb. 2001, “Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy,” Immunity. 14(2):105-110. [cited by applicant]
Waldrop et al., Apr. 1997, “Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency,” … [cited by applicant]
Walter et al., Oct. 1995, “Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor,” The New England Journal of Medicine, 333(16):1… [cited by applicant]
Wherry et al., Mar. 2003, “Lineage relationship and protective immunity of memory CD8 T cell subsets,” Nat Immunol. 4(3):225-234. [cited by applicant]
Wilkie et al., Jul.-Aug. 2004, “Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases,” Journal of Immunotherapy, 27(4):309-316. [cited by applicant]
Wolfl et al., Feb. 2011, “Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy,” Cancer Immunol Immunother. 60(2):173-186. [cited by applicant]
Written Opinion dated Nov. 29, 2019 of International Patent Application No. PCT/US2017/034364, filed May 25, 2017 (published as WO2018/217203), 6 pages. [cited by applicant]
Xu et al., May 2013, “Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma,” Cancer Res. 15;73(10):3075-30… [cited by applicant]
Yu et al., Dec. 2010, “Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model,” Clin Cancer Res. 16(24)… [cited by applicant]
Yu et al., Apr. 2012, “Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model,” Proc Natl Acad Sci U S A. 109(16):6187-6192. [cited by applicant]
Zhang et al., May 1998, “Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15,” Immunity. 8(5):591-599. [cited by applicant]
Zhang et al., Jun. 2012, “Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice,” J Immunol. 188(12… [cited by applicant]
Takai, Aug. 2002, “Roles of Fc receptors in autoimmunity,” Nature 2(8): 580-592. [cited by applicant]
Tamzalit et al., 2014, “IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells,” PNAS 111(23):8565-8570. [cited by applicant]